Rapport Therapeutics, Inc. (NasdaqGM: RAPP)
Health Care · Pharmaceuticals · US
$30.65
-4.72% today · +17.0% 1Y
Rapport Therapeutics, Inc. (NasdaqGM: RAPP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.47B and employs 84 people.
Over the last twelve months the share price has gained 17.0%, trading between 23.75 and 52.93.
Tweenvest scores Rapport Therapeutics, Inc. across four factors: quality 48/100, value 64/100. Its strongest factor is value.
RAPP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.47B
- Revenue (TTM)
- $20.00M
- P/E
- —
- EPS
- -3.05
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $52.93
- 52-week low
- $23.75
- Avg volume (3M)
- —
- Shares outstanding
- 47.98M
- Employees
- 84
- Next earnings
- —
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
- ISIN
- US75383L1026
- Founded
- 2022
- Listed since
- Jun 7, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical Co.,LtdSZSE: 300026 | $1.49B | CN¥3.32 | +2.15% |
| Jiangxi Fushine Pharmaceutical Co., Ltd.SZSE: 300497 | $1.48B | CN¥18.43 | +3.19% |
| Mayinglong Pharmaceutical Group Co., Ltd.SHSE: 600993 | $1.48B | CN¥22.95 | +1.91% |
| Concord Biotech LimitedNSEI: CONCORDBIO | $1.47B | Rs1,361.40 | -0.92% |
| Zhejiang Hisoar Pharmaceutical Co., Ltd.SZSE: 002099 | $1.46B | CN¥6.32 | +2.76% |
| NATCO Pharma LimitedNSEI: NATCOPHARM | $1.46B | Rs789.40 | -3.88% |
| Zhejiang Jingxin Pharmaceutical Co., Ltd.SZSE: 002020 | $1.45B | CN¥11.87 | +0.34% |
| Guangdong Taienkang Pharmaceutical Co., Ltd.SZSE: 301263 | $1.45B | CN¥19.14 | +0.26% |
Figures last refreshed Oct 11, 2026.